Jennifer Wilkinson Carlisle

15PUBLICATIONS
75CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMedical molecular engineering of nucleic acids and proteinsCommercial lawApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 08, 2026
Real-World Implementation of Tarlatamab-Dlle Therapy for Patients With Extensive-Stage Small Cell Lung Cancer and Other High-Grade Neuroendocrine Neoplasms.

|Mar 26, 2026
Exposed phosphatidylserine is an inhibitory molecule in T cell exhaustion.

Christopher B Medina, Ewelina Sobierajska, Minghao Gong

|May 21, 2025
Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration.

Jennifer W Carlisle, Zachary Wolner, Sagal Pannu

|May 01, 2025
Safety and Tolerability of Lete-cel in NSCLC-Reply.

Mehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann

|Jan 29, 2025
Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.

Jacob M Sands, Stéphane Champiat, Horst-Dieter Hummel

|Nov 22, 2024
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer.

Mehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann

Pageof 3

Frequent Collaborators

7 joint publications

Suresh S Ramalingam

4 joint publications

Taofeek Kunle Owonikoko

4 joint publications

Ticiana Leal

3 joint publications

Ramaswamy Govindan